<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136161</url>
  </required_header>
  <id_info>
    <org_study_id>RUTISAPH2</org_study_id>
    <nct_id>NCT01136161</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Archivel Farma S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Archivel Farma S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess the safety, tolerability and immunogenicity of two doses of
      RUTI® vaccine administered four weeks apart after one month pre-treatment with INH.

      The trial will be double-blinded, randomized and placebo-controlled with 96 subjects (48 HIV-
      and 48 HIV+ subjects).

      Three different RUTI® doses and placebo will be tested, randomizing assigned both in HIV+ and
      HIV- subjects. Each subject will be randomized to receive one of the four treatments
      (placebo, 5, 25, 50 μg), after completion of one month INH pre-treatment (one tablet of
      300mg/day, vp.o.). Each subject will receive two administrations of the same treatment, 28
      days apart. Subjects will be monitored until one month after the second inoculation with
      RUTI®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RUTI is a therapeutic vaccine made from virulent M.tuberculosis bacteria, grown in stressful
      conditions, fragmented, detoxified, heat inactivated (FCMtb) and liposomed. RUTI provides a
      strong humoral and cellular immune response against antigens from active growing and latent
      bacilli but also against structural antigens, as it has been proved in animal models of
      latent tuberculosis infection and in phase I clinical trial of Healthy Volunteers. The
      vaccine has been designed to be used against Latent Tuberculosis Infection as a therapeutic
      vaccine after 1-month of chemotheraputic treatment, instead the current treatment based on
      6-9 months of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>84 days</time_frame>
    <description>The investigator will evaluate the site of injection for redness, pain, swelling, and induration and functional limitation.
Redness, swelling and induration will be evaluated and recorded on the CRF as: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. If present, the extent of the reaction will be measured in mm. Pain will be recorded, after questioning the subjects, by means of a Visual Analogue Scale (VAS from 0 to 100). The presence of abscess, ulceration or necrosis will also be evaluated, measured and adequately documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Focal Tolerability</measure>
    <time_frame>84 days</time_frame>
    <description>Evaluation of the hilar lymph nodes for inflammation: An un-contrasted thoracic computerised tomographic scan will be performed to evaluate the change in size of the hilar lymph nodes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic tolerability</measure>
    <time_frame>84 days</time_frame>
    <description>Body temperature ≥38ºC, asthenia, sweating, malaise, headache, dizziness, nausea, myalgia, arthralgia, rash and generalised pruritus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs and physical examination</measure>
    <time_frame>84 days</time_frame>
    <description>Blood pressure (systolic and diastolic), pulse, respiratory rate, body temperature and full physical examination will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>84 days</time_frame>
    <description>The following ECG parameters will be measured: Bits Frequency Heart rate, PR, QRS, QT and QTc (Bazett) intervals. Any other anomaly on the ECG (such as U wave, ischaemia, rhythm and conduction disturbances) will be evaluated by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Tests</measure>
    <time_frame>84 days</time_frame>
    <description>Blood samples for serum chemistry and haematology and urine sample for urinalysis will be taken under fasting conditions for evaluation of laboratory safety parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>63 days</time_frame>
    <description>Samples to perform immunogenicity testing will be collected at specified visits. Cellular mediated immunity (ELISPOT and ELISA techniques), IFN-gama Spot Forming Units after stimulation for 18 hours with five stimuli, WHO assay (stimulating whole blood 7days with PPD) and TIGRA (TSPOT TB assay).
Peripheral blood mononuclear cells will be frozen for future immune assays. Sera will be frozen to be further tested for the antibody-mediated immunity against M.tuberculosis antigens</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>RUTI 5 micrograms of FCMtb in HIV -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 25 micrograms of FCMtb in HIV -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 50 micrograms of FCMtb in HIV -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI Matching Placebo in HIV -</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 5 micrograms of FCMtb in HIV +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 25 micrograms of FCMtb in HIV +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 50 micrograms of FCMtb in HIV +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI Matching Placebo in HIV +</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>n=12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.</description>
    <arm_group_label>RUTI 5 micrograms of FCMtb in HIV -</arm_group_label>
    <arm_group_label>RUTI 5 micrograms of FCMtb in HIV +</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.</description>
    <arm_group_label>RUTI 25 micrograms of FCMtb in HIV -</arm_group_label>
    <arm_group_label>RUTI 25 micrograms of FCMtb in HIV +</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.</description>
    <arm_group_label>RUTI 50 micrograms of FCMtb in HIV -</arm_group_label>
    <arm_group_label>RUTI 50 micrograms of FCMtb in HIV +</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI Matching Placebo</intervention_name>
    <description>Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.</description>
    <arm_group_label>RUTI Matching Placebo in HIV -</arm_group_label>
    <arm_group_label>RUTI Matching Placebo in HIV +</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Asymptomatic adult aged 18 up to 50 years.

          2. No evidence of active TB (Section 8).

          3. No clinically significant finding at the discretion of the investigator.

          4. Willingness to undergo an HIV test.

          5. Resident in or near trial site for the duration of the trial.

          6. Willingness to allow the investigators to discuss the patient's medical history with
             his usual doctor or HIV physician.

          7. No donation of blood for 56 days prior to screening and agreement to refrain from
             blood donation during the trial.

          8. Willing and able to provide written informed consent.

          9. Positive tuberculin skin test (TST +), (≥5 mm induration) and Quantiferon TB Gold
             positive result (according to manufacturers instructions).

         10. Reliable contraception to be used by female subjects during the clinical trial.

         11. Additional inclusion criteria for HIV+ groups:

               -  HIV antibody positive.

               -  CD4 count ≥350 cells/mL3 on a single CD4 count at the period of screening.

               -  Subjects on anti-retroviral treatment can be included if clinically stable.

        Exclusion Criteria:

          1. Any deviation from the normal range in biochemistry or haematology blood tests or in
             urine analysis that is considered to be clinically significant at the discretion of
             the investigator. Values of Hb, WCC, platelet count, AST/ALT and creatinine should be
             in a normal range accordingly to the normal laboratory values.

          2. Use of any investigational or non-registered drug, vaccine, or medical device other
             than the trial vaccine within 30 days prior to dosing of trial vaccine, or planned use
             during the trial period.

          3. Administration of chronic (defined as more than 14 days) immunosuppressive drugs
             within six months of vaccination and required throughout the duration of the trial
             (for corticosteroids this means prednisolone or equivalent at ≥ 0.5 mg/kg/day).

          4. Female of child bearing potential who intends to become pregnant during the trial.

          5. Females who are pregnant, lactating, or of child bearing potential with a blood HCG
             positive result 24-48 hours at the screening period, or prior to every injection of
             RUTI®.

          6. Any AIDS defining illness according to the CDC classification system for HIV
             infection.

          7. Presence of active (previously undiagnosed) TB or being on TB treatment.

          8. Suspected or known current alcohol abuse (alcohol intake questionnaire.

          9. Suspected or known substance abuse.

         10. Presence of any underlying disease, specifically autoimmune disease, asthma,
             angioedema, bleeding disorders, uncontrolled hypertension and diabetes, and any other
             disease that compromises the diagnosis and evaluation of response to the vaccine,
             excluding HIV.

         11. Administration of immunoglobulins and/or any blood products within three months prior
             to the planned administration of the vaccine.

         12. Any history of anaphylaxis in reaction to vaccination and/or other medication.

         13. Investigator assessment of lack of understanding or willingness to participate and
             comply with all requirements of the trial protocol.

         14. Any other finding which in the opinion of the investigator would significantly
             increase the risk of having an adverse outcome from participating in the trial.

         15. Exclusion criteria relating to INH pre-treatment

               -  Weight less than 40 kg.

               -  Known or suspected hypersensitivity to INH.

               -  Self reported chronic liver disease or symptoms suggesting active hepatitis
                  (jaundice, nausea, vomiting, right upper quadrant pain, dark urine, pale stools).

               -  Alcohol use exceeding 28 units per week (men) or 21 units per week (women) (see
                  alcohol intake questionnaire, Appendix 17.2).

               -  History of convulsions.

               -  History of psychosis.

               -  Peripheral neuropathy grade 2 or greater.

               -  Three months post-partum.

               -  Concomitant medication with phenytoin, carbamazepine; warfarin; theophylline;
                  disulfiram; selective serotonin re-uptake inhibitor antidepressants (e.g.
                  citalopram, fluoxetine, paroxetine, sertraline); oral ketoconazole or
                  itraconazole.

         16. Additional exclusion criterion for HIV negative groups:

             • Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             asplenia.

         17. Additional exclusion criterion for HIV+ groups • CD4 count &lt; 350 cells/mL3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André S Nell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel Int. Bloemfontein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pere Joan Cardona, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Archivel Farma S.L.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Int. Bloemfontein</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel Int. George</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel Int. Port Elizabeth</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.germanstrias.org/</url>
    <description>Fundació Institut Investigació en Ciències de la Salut Germans Trias i Pujol homepage</description>
  </link>
  <link>
    <url>http://www.archivelfarma.com</url>
    <description>Archivel Farma, S.L. homepage</description>
  </link>
  <reference>
    <citation>Gil O, Díaz I, Vilaplana C, Tapia G, Díaz J, Fort M, Cáceres N, Pinto S, Caylà J, Corner L, Domingo M, Cardona PJ. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS One. 2010 Apr 6;5(4):e10030. doi: 10.1371/journal.pone.0010030.</citation>
    <PMID>20386605</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ. Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease. Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):7-14. doi: 10.1007/s00005-009-0062-5. Epub 2010 Jan 5. Review.</citation>
    <PMID>20049645</PMID>
  </reference>
  <reference>
    <citation>Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010 Jan 22;28(4):1106-16. doi: 10.1016/j.vaccine.2009.09.134. Epub 2009 Oct 22.</citation>
    <PMID>19853680</PMID>
  </reference>
  <reference>
    <citation>Domingo M, Gil O, Serrano E, Guirado E, Nofrarias M, Grassa M, Cáceres N, Pérez B, Vilaplana C, Cardona PJ. Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. Scand J Immunol. 2009 Jun;69(6):500-7. doi: 10.1111/j.1365-3083.2009.02251.x.</citation>
    <PMID>19439010</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection. 2009 Apr;37(2):80-6. doi: 10.1007/s15010-008-8087-y. Epub 2009 Mar 23. Review.</citation>
    <PMID>19308318</PMID>
  </reference>
  <reference>
    <citation>Gil O, Vilaplana C, Guirado E, Díaz J, Cáceres N, Singh M, Cardona PJ. Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol. 2008 Nov;15(11):1742-4. doi: 10.1128/CVI.00255-08. Epub 2008 Sep 30.</citation>
    <PMID>18827194</PMID>
  </reference>
  <reference>
    <citation>Guirado E, Gil O, Cáceres N, Singh M, Vilaplana C, Cardona PJ. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol. 2008 Aug;15(8):1229-37. doi: 10.1128/CVI.00094-08. Epub 2008 Jun 4.</citation>
    <PMID>18524883</PMID>
  </reference>
  <reference>
    <citation>Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montané E, Singh M, Spallek R, Ausina V, Cardona PJ. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol. 2008 Jun;67(6):610-7. doi: 10.1111/j.1365-3083.2008.02103.x. Epub 2008 Apr 4.</citation>
    <PMID>18397200</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets. 2007 Mar;6(1):27-39. Review.</citation>
    <PMID>17352686</PMID>
  </reference>
  <reference>
    <citation>Guirado E, Amat I, Gil O, Díaz J, Arcos V, Caceres N, Ausina V, Cardona PJ. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect. 2006 Apr;8(5):1252-9. Epub 2006 Jan 27.</citation>
    <PMID>16702016</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006 May-Jul;86(3-4):273-89. Epub 2006 Mar 20. Review.</citation>
    <PMID>16545981</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, Vilaplana C, Tapia G, Ausina V. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005 Feb 3;23(11):1393-8.</citation>
    <PMID>15661388</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LTBI (Latent Tuberculosis Infection)</keyword>
  <keyword>TB (Tuberculosis)</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

